<p>Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX - 獲取免費報告）週二股價上漲了 5.4%。該股最高交易價為 5.85 美元，最後交易價為 5.81 美元。在午盤交易中，共成交 3,085,222 股，較平均交易量 11,835,804 股下降了 74%。該股此前收盤價為 5.51 美元。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 寵兒嗎？</li>
</ul>
<p>RXRX 已成為多份研究分析報告的主題。Leerink Partners 在 2 月 28 日的報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並給予該公司 “市場表現” 評級。KeyCorp 在 1 月 8 日的報告中將 Recursion Pharmaceuticals 的目標價從 12.00 美元下調至 10.00 美元，並給予該公司 “增持” 評級。Needham &amp; Company LLC 在 4 月 8 日的報告中重申了 “買入” 評級，並將 Recursion Pharmaceuticals 的目標價設定為 11.00 美元。Cowen 在 2 月 28 日的報告中重申了對 Recursion Pharmaceuticals 的 “持有” 評級。最後，摩根士丹利在 4 月 10 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 10.00 美元下調至 8.00 美元，並給予該公司 “等權重” 評級。四位研究分析師對該股給予了持有評級，兩位分析師給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，共識目標價為 8.20 美元。</p>
<p><strong>獲取我們最新的 RXRX 股票分析</strong></p>
<h2>Recursion Pharmaceuticals 股價上漲 0.7%</h2>
<ul>
<li>生物科技的邊緣：兩隻潛力巨大的股票</li>
</ul>
<p>該公司的市值為 22.3 億美元，市盈率為-3.63，貝塔值為 1.00。該股的 50 日移動平均線為 6.78 美元，200 日移動平均線為 6.82 美元。該公司的債務與股本比率為 0.04，流動比率為 4.35，速動比率為 4.35。</p>
<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）最近於 2 月 28 日發佈了其財報。該公司報告本季度每股收益（EPS）為-0.53 美元，低於市場共識預期的-0.36 美元，差額為-0.17 美元。Recursion Pharmaceuticals 的淨利潤率為-579.52%，股本回報率為-76.56%。該公司本季度的收入為 460 萬美元，而分析師預期為 1904 萬美元。去年同期，該公司每股收益為-0.42 美元。Recursion Pharmaceuticals 的季度收入較去年同期下降了 57.8%。研究分析師預計 Recursion Pharmaceuticals, Inc.在本年度將發佈-1.57 美元的每股收益。</p>
<h2>對 Recursion Pharmaceuticals 的對沖基金觀點</h2>
<ul>
<li>AI 製藥：通往 AI 驅動藥物投資的兩條路徑</li>
</ul>
<p>一些機構投資者最近調整了對 RXRX 的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 40.1%。先鋒集團目前擁有 34,009,994 股該公司的股票，價值 229,908,000 美元，此前在上個季度增持了 9,737,196 股。軟銀集團（Softbank Group CORP.）在第四季度新建了對 Recursion Pharmaceuticals 的持倉，價值約 99,152,000 美元。道富集團（State Street Corp）在第三季度將其在 Recursion Pharmaceuticals 的持倉增加了 47.1%。道富集團目前擁有 12,870,272 股該公司的股票，價值 84,815,000 美元，此前在上個季度增持了 4,120,685 股。Novo Holdings A S 在第四季度新建了對 Recursion Pharmaceuticals 的持倉，價值約 68,375,000 美元。最後，Geode Capital Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持倉增加了 12.1%。Geode Capital Management LLC 目前擁有 6,087,149 股該公司的股票，價值 41,160,000 美元，此前在上個季度增持了 655,238 股。機構投資者和對沖基金持有該公司 89.06% 的股份。</p>
<h2>關於 Recursion Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Recursion Pharmaceuticals, Inc.是一家臨牀階段的生物技術公司，通過整合生物學、化學、自動化、數據科學和工程等技術創新，致力於解碼生物學，以工業化藥物發現。該公司開發的 REC-994 正在進行治療腦血管畸形的二期臨牀試驗；REC-2282 正在進行治療神經纖維瘤病 2 型的二期/三期臨牀試驗；REC-4881 正在進行治療家族性腺瘤性息肉病的一期 b/二期臨牀試驗；REC-3964 正在進行治療艱難梭狀芽胞桿菌感染的一期臨牀試驗；REC-4881 正在進行治療 AXIN1 或 APC 突變癌症的二期臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Recursion Pharmaceuticals</li>
<li>如何投資科技股及值得考慮的頂尖科技股</li>
<li>當心 BigBear.ai：內部人士正在出售——你應該買嗎？</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>隨着網絡威脅環境的擴大，CrowdStrike 股票值得購買</li>
<li>股票情緒分析：它是如何工作的</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
<p>在考慮 Recursion Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Recursion Pharmaceuticals 並不在名單上。</p>
<p>雖然 Recursion Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RXRX

<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX）股價上漲 5.4%，至 5.81 美元，儘管交易量大幅下降。分析師意見不一，目標價格範圍從 6.00 美元到 11.00 美元不等。該公司報告的季度每股收益為-0.53 美元，未達到預期，且收入同比下降 57.8%。機構投資者持有 89.06% 的股份，顯示出強烈的興趣。Recursion 專注於藥物發現，目前有多個候選藥物處於不同的臨牀試驗階段</p>

<p>Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares traded up 5.4% on Tuesday . The stock traded as high as $5.85 and last traded at $5.81. 3,085,222 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 11,835,804 shares. The stock had previously closed at $5.51.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX - 獲取免費報告）週二股價上漲了 5.4%。該股最高交易價為 5.85 美元，最後交易價為 5.81 美元。在午盤交易中，共成交 3,085,222 股，較平均交易量 11,835,804 股下降了 74%。該股此前收盤價為 5.51 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 寵兒嗎？</li>
</ul>
</div><p>RXRX has been the subject of several research analyst reports. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;market perform&#34; rating for the company in a report on Friday, February 28th. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, January 8th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Cowen reaffirmed a &#34;hold&#34; rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an &#34;equal weight&#34; rating for the company in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $8.20.</p>
<div class="lb-trans"><p>RXRX 已成為多份研究分析報告的主題。Leerink Partners 在 2 月 28 日的報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並給予該公司 “市場表現” 評級。KeyCorp 在 1 月 8 日的報告中將 Recursion Pharmaceuticals 的目標價從 12.00 美元下調至 10.00 美元，並給予該公司 “增持” 評級。Needham &amp; Company LLC 在 4 月 8 日的報告中重申了 “買入” 評級，並將 Recursion Pharmaceuticals 的目標價設定為 11.00 美元。Cowen 在 2 月 28 日的報告中重申了對 Recursion Pharmaceuticals 的 “持有” 評級。最後，摩根士丹利在 4 月 10 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 10.00 美元下調至 8.00 美元，並給予該公司 “等權重” 評級。四位研究分析師對該股給予了持有評級，兩位分析師給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，共識目標價為 8.20 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on RXRX</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 RXRX 股票分析</strong></p>
</div><h2>Recursion Pharmaceuticals Stock Up 0.7 %</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 股價上漲 0.7%</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技的邊緣：兩隻潛力巨大的股票</li>
</ul>
</div><p>The company has a market cap of $2.23 billion, a P/E ratio of -3.63 and a beta of 1.00. The stock has a 50-day moving average of $6.78 and a 200 day moving average of $6.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.</p>
<div class="lb-trans"><p>該公司的市值為 22.3 億美元，市盈率為-3.63，貝塔值為 1.00。該股的 50 日移動平均線為 6.78 美元，200 日移動平均線為 6.82 美元。該公司的債務與股本比率為 0.04，流動比率為 4.35，速動比率為 4.35。</p>
</div><p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. Recursion Pharmaceuticals's quarterly revenue was down 57.8% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）最近於 2 月 28 日發佈了其財報。該公司報告本季度每股收益（EPS）為-0.53 美元，低於市場共識預期的-0.36 美元，差額為-0.17 美元。Recursion Pharmaceuticals 的淨利潤率為-579.52%，股本回報率為-76.56%。該公司本季度的收入為 460 萬美元，而分析師預期為 1904 萬美元。去年同期，該公司每股收益為-0.42 美元。Recursion Pharmaceuticals 的季度收入較去年同期下降了 57.8%。研究分析師預計 Recursion Pharmaceuticals, Inc.在本年度將發佈-1.57 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Recursion Pharmaceuticals 的對沖基金觀點</h2>
</div><ul>
<li>AI Pharma: 2 Paths to AI-Powered Drug Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>AI 製藥：通往 AI 驅動藥物投資的兩條路徑</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of RXRX. Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $99,152,000. State Street Corp increased its position in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Novo Holdings A S acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Finally, Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 12.1% during the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after buying an additional 655,238 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對 RXRX 的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 40.1%。先鋒集團目前擁有 34,009,994 股該公司的股票，價值 229,908,000 美元，此前在上個季度增持了 9,737,196 股。軟銀集團（Softbank Group CORP.）在第四季度新建了對 Recursion Pharmaceuticals 的持倉，價值約 99,152,000 美元。道富集團（State Street Corp）在第三季度將其在 Recursion Pharmaceuticals 的持倉增加了 47.1%。道富集團目前擁有 12,870,272 股該公司的股票，價值 84,815,000 美元，此前在上個季度增持了 4,120,685 股。Novo Holdings A S 在第四季度新建了對 Recursion Pharmaceuticals 的持倉，價值約 68,375,000 美元。最後，Geode Capital Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持倉增加了 12.1%。Geode Capital Management LLC 目前擁有 6,087,149 股該公司的股票，價值 41,160,000 美元，此前在上個季度增持了 655,238 股。機構投資者和對沖基金持有該公司 89.06% 的股份。</p>
</div><h2>About Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Recursion Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.是一家臨牀階段的生物技術公司，通過整合生物學、化學、自動化、數據科學和工程等技術創新，致力於解碼生物學，以工業化藥物發現。該公司開發的 REC-994 正在進行治療腦血管畸形的二期臨牀試驗；REC-2282 正在進行治療神經纖維瘤病 2 型的二期/三期臨牀試驗；REC-4881 正在進行治療家族性腺瘤性息肉病的一期 b/二期臨牀試驗；REC-3964 正在進行治療艱難梭狀芽胞桿菌感染的一期臨牀試驗；REC-4881 正在進行治療 AXIN1 或 APC 突變癌症的二期臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Recursion Pharmaceuticals</li>
<li>如何投資科技股及值得考慮的頂尖科技股</li>
<li>當心 BigBear.ai：內部人士正在出售——你應該買嗎？</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>隨着網絡威脅環境的擴大，CrowdStrike 股票值得購買</li>
<li>股票情緒分析：它是如何工作的</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Recursion Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Recursion Pharmaceuticals 並不在名單上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Recursion Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Recursion Pharmaceuticals（納斯達克股票代碼：RXRX）股價上漲 5.4% - 現在是買入的好時機嗎？